HALAVEN is a prescription medicine for adults with metastatic breast cancer (mBC) who have already received at least 2 other types of anticancer medicines for their breast cancer once it has spread to other parts of the body. Previous therapy should have included an anthracycline and a taxane for either early or advanced breast cancer.
When used alone after 2 prior chemotherapies for mBC, HALAVEN is the only chemotherapy that has been proven in a clinical trial to help some women live longer. Although some women lived longer and some women did not live as long, women who were treated with HALAVEN in a clinical trial lived an average of 13.2 months compared with women treated with other chemotherapy or hormone therapy, who lived an average of 10.6 months.
HALAVEN was studied in women with all types of tumor receptors. This means that their ER/PR hormone receptors (estrogen/progesterone receptors) were either positive or negative and their HER2 receptors (human epidermal growth factor receptor 2) were either positive or negative.
It's a decision that only you and your health care team can make. That decision will depend on a discussion that might include
To help with the discussion, you can download the Can we talk about HALAVEN? discussion guide below, fill it out with your information, print it, and bring it with you to your next appointment.Go to discussion guide